Bio-Rad Laboratories A (BIO) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Outperform | $390.00 from $370.00 | Aug 7, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $330.00 from $310.00 | Aug 5, 2026 |
| RBC Capital | Maintained | Outperform | $370.00 from $320.00 | Aug 5, 2026 |
| Citigroup | Maintained | Neutral | $330.00 from $300.00 | Aug 5, 2026 |
| RBC Capital | Maintained | Outperform | $320.00 | May 15, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $290.00 from $320.00 | May 1, 2026 |
| Citigroup | Downgraded | Buy → Neutral | $300.00 from $375.00 | Apr 7, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $340.00 from $265.00 | Oct 30, 2025 |
| Citigroup | Maintained | Buy | $375.00 from $350.00 | Oct 30, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $265.00 from $245.00 | Aug 1, 2025 |
| RBC Capital | Maintained | Outperform | $409.00 from $387.00 | Aug 1, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $245.00 from $260.00 | Jun 9, 2025 |
| RBC Capital | Maintained | Outperform | $392.00 from $409.00 | May 2, 2025 |
| Citigroup | Maintained | Buy | $350.00 from $400.00 | May 2, 2025 |
| UBS | Maintained | Buy | $310.00 from $355.00 | May 2, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $270.00 from $320.00 | Apr 17, 2025 |
| Wells Fargo | Maintained | Equal-Weight | $345.00 from $360.00 | Feb 12, 2025 |
| RBC Capital | Maintained | Outperform | $481.00 | Jan 14, 2025 |
| RBC Capital | Maintained | Outperform | $481.00 from $369.00 | Dec 9, 2024 |
| RBC Capital | Maintained | Outperform | $469.00 from $446.00 | Oct 31, 2024 |
Frequently asked questions
What is the price target for BIO stock?
The average 12-month analyst price target for Bio-Rad Laboratories A (BIO) is $350.00, with a high estimate of $390.00 and a low of $330.00, across 3 analysts.
Is BIO a buy, sell, or hold?
Analysts covering Bio-Rad Laboratories A currently average a Hold rating: 1 buy, 4 hold and 2 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for BIO?
The average price target of $350.00 implies 9.27% downside from the last price of $385.76.
What is the latest analyst rating on BIO?
On Aug 7, 2026, RBC Capital maintained Bio-Rad Laboratories A at Outperform with a price target of $390.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.